AR119317A1 - Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 - Google Patents

Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1

Info

Publication number
AR119317A1
AR119317A1 ARP200101852A ARP200101852A AR119317A1 AR 119317 A1 AR119317 A1 AR 119317A1 AR P200101852 A ARP200101852 A AR P200101852A AR P200101852 A ARP200101852 A AR P200101852A AR 119317 A1 AR119317 A1 AR 119317A1
Authority
AR
Argentina
Prior art keywords
positive
allesteric
modulator
tetrahydroisoquinoline derivative
substituted tetrahydroisoquinoline
Prior art date
Application number
ARP200101852A
Other languages
English (en)
Inventor
Anne Valade
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of AR119317A1 publication Critical patent/AR119317A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

La presente se refiere a compuestos de acuerdo con la fórmula (1) que son moduladores alostéricos positivos de D1 y, en consecuencia, son beneficiosos como agentes farmacéuticos para el tratamiento de enfermedades en las cuales los receptores D1 juegan un papel. Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula (1), o una sal aceptable para uso farmacéutico del mismo.
ARP200101852A 2019-07-01 2020-06-30 Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 AR119317A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19183641 2019-07-01

Publications (1)

Publication Number Publication Date
AR119317A1 true AR119317A1 (es) 2021-12-09

Family

ID=67137842

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101852A AR119317A1 (es) 2019-07-01 2020-06-30 Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1

Country Status (20)

Country Link
US (1) US20220251064A1 (es)
EP (1) EP3993795A1 (es)
JP (1) JP2022537994A (es)
KR (1) KR20220029687A (es)
CN (1) CN114008032B (es)
AR (1) AR119317A1 (es)
AU (1) AU2020299705A1 (es)
BR (1) BR112021022379A2 (es)
CA (1) CA3139622A1 (es)
CL (1) CL2021002949A1 (es)
CO (1) CO2021017740A2 (es)
EC (1) ECSP22007557A (es)
IL (1) IL289317A (es)
MA (1) MA56445A (es)
MX (1) MX2021015872A (es)
PE (1) PE20220373A1 (es)
SG (1) SG11202112539XA (es)
TW (1) TW202115009A (es)
WO (1) WO2021001286A1 (es)
ZA (1) ZA202109194B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4304577A1 (en) * 2021-03-09 2024-01-17 Eli Lilly And Co. Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101668746A (zh) 2007-03-01 2010-03-10 詹森药业有限公司 作为组胺h3受体调节剂的四氢异喹啉化合物
KR101284796B1 (ko) 2011-10-05 2013-07-10 (주)포인트엔지니어링 캔 패지키 타입의 광 디바이스 제조 방법 및 이에 의해 제조된 광 디바이스
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
CN107001278B (zh) * 2014-10-08 2020-11-24 Ucb生物制药私人有限公司 四氢异喹啉衍生物
EP3442945B1 (en) * 2016-04-13 2020-07-08 UCB Biopharma SRL Tetrahydroisoquinoline derivatives
TWI725408B (zh) 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑

Also Published As

Publication number Publication date
AU2020299705A1 (en) 2021-12-09
ZA202109194B (en) 2023-11-29
ECSP22007557A (es) 2022-02-25
IL289317A (en) 2022-02-01
BR112021022379A2 (pt) 2022-03-08
PE20220373A1 (es) 2022-03-16
TW202115009A (zh) 2021-04-16
CA3139622A1 (en) 2021-01-07
WO2021001286A1 (en) 2021-01-07
JP2022537994A (ja) 2022-08-31
EP3993795A1 (en) 2022-05-11
MA56445A (fr) 2022-05-11
MX2021015872A (es) 2022-02-03
SG11202112539XA (en) 2021-12-30
CN114008032A (zh) 2022-02-01
CL2021002949A1 (es) 2022-07-15
US20220251064A1 (en) 2022-08-11
CN114008032B (zh) 2023-11-10
CO2021017740A2 (es) 2022-01-17
KR20220029687A (ko) 2022-03-08

Similar Documents

Publication Publication Date Title
DOP2022000124A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
CR20160212A (es) Composiciones y métodos para modular los receptores x farnesoides
CO2019010078A2 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
AR108046A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
CL2023001369A1 (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
UY37742A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CO2019010578A2 (es) Derivados de fenilo como moduladores del receptor de pge2
CL2021002946A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
DOP2023000251A (es) Compuestos oligoméricos que inhiben la expresión de hsd17b13
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
CO2021014210A2 (es) Compuestos de pirrol
UY36124A (es) Derivados de carboxamida
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
AR119317A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
CO2021004873A2 (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
AR110481A1 (es) MODULADORES DE ROR g (RORg)
PE20211454A1 (es) Derivados de imidazopiridina y su uso como medicamento
CO2021017202A2 (es) Compuestos tricíclicos
DOP2021000028A (es) Formulaciones de dendrímeros
ECSP23041779A (es) Un derivado de tetrahidroisoquinolina sustituido como un modulador alostérico positivo de d1